Biotech Archives - Page 704 of 795

2 minute read

Strata Oncology Announces Expansion Of Clinical Collaboration With Pfizer For Strata PATH Trial Into Early-Stage Cancer

September 13, 8:51 AM

Pfizer to provide therapeutics approved in late-stage cancer indications for new micrometastatic patient cohorts ANN ARBOR, Mich., Sept. 13, 2022 /PRNewswire/ -- Strata Oncology, Inc. a

PFE

1 minute read

Oramed Reports Top-Line Results From Phase 2 NASH Trial With Its ORMD-0801, Oral Insulin Candidate; Met Primary And Secondary Endpoint

By Bill Haddad

September 13, 8:46 AM

Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using

ORMP

1 minute read

Nuvectis Pharma Announces Data for NXP800 In A Preclinical Model Of ARID1a-Mutated Gastric Carcinoma

By Benzinga Newsdesk

September 13, 8:32 AM

FORT LEE, N.J., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the

NVCT

1 minute read

Seelos Therapeutics Announces Participation Of Acadia Healthcare In The Registration Directed Study Of SLS-002 (Intranasal Racemic Ketamine) For Acute Suicidal Ideation And Behavior In Patients With Major Depressive Disorder

By Bill Haddad

September 13, 8:08 AM

NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,

ACHC

1 minute read

Pardes Biosciences Announces Commencement Of Phase 2 Trial Evaluating PBI-0451 For The Treatment Of SARS-CoV-2 Infections

By Benzinga Newsdesk

September 13, 8:04 AM

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1 2023

PRDS

2 minute read

aTyr Pharma Receives FDA Fast Track Designation For Efzofitimod For Treatment Of Systemic Sclerosis-Associated Interstitial Lung Disease

By Benzinga Newsdesk

September 13, 8:01 AM

aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S.

LIFE

5 minute read

FDA Schedules AdComm Review For First Over The Counter Birth Control Pill

By Vandana Singh

September 13, 6:40 AM

The FDA has set a date to review what could become the first over-the-counter birth control pill approved in the…

PRGO

1 minute read

At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs

By Vandana Singh

September 13, 6:15 AM

Alpine Immune Sciences Inc (NASDAQ:ALPN) announced clinical updates from ALPN-303 and davoceticept programs. Key highlights from the announcement include: ALPN-303 Well…

ALPN